Antimicrobial peptide Cathelicidin-BF prevents intestinal barrier dysfunction in a mouse model of endotoxemia

International Immunopharmacology

Volumn 25, Issue 1, 2015, Pages 141-147

  Song, Deguang ^a   Zong, Xin ^a   Zhang, Haiwen ^a   Wang, Tenghao ^a   Yi, Hongbo ^a   Luan, Chao ^a   Wang, Yizhen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antimicrobial peptide; Apoptosis; Intestinal permeability; NF B; Tight junction

Indexed keywords

CATHELICIDIN; CATHELICIDIN BF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; SNAKE VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTOXEMIA; HISTOPATHOLOGY; INTESTINE EPITHELIUM CELL; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIGHT JUNCTION; ANIMAL; BUNGARUS; CELL LINE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; HUMAN; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTESTINE; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BUNGARUS; CATHELICIDINS; CELL LINE; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; EPITHELIAL CELLS; HUMANS; INTESTINES; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; NF-KAPPA B; SIGNAL TRANSDUCTION; SNAKE VENOMS; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922230135     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.01.017     Document Type: Article

References (35)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Yu P, Martin CM. Increased gut permeability and bacterial translocation in Pseudomonas pneumonia-induced sepsis. Crit Care Med 2000;28:2573-7.
3. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut. Shock 2001;15:1-10.
4. Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003;18:479-97.
5. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal-tract-the importance of apoptosis. J Cell Sci 1994;107: 3569-77.
6. Watson AJM, Chu SY, Sieck L, Gerasimenko O, Bullen T, Campbell F, et al. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 2005;129:902-12.
7. Li QR, Zhang Q, Wang CY, Liu XX, Li N, Li JS. Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol 2009; 218:210-21.
8. Lai CW, Sun TL, Lo W, Tang ZH, Wu S, Chang YJ, et al. Shedding-induced gap formation contributes to gut barrier dysfunction in endotoxemia. J Trauma Acute Care 2013;74:203-13.
9. Li HM, Wang YY, Wang HD, Cao WJ, Yu XH, Lu DX, et al. Berberine protects against lipopolysaccharide-induced intestinal injury in mice via alpha 2 adrenoceptorindependent mechanisms. Acta Pharmacol Sin 2011;32:1364-72.
10. Williams JM, Duckworth CA, Watson AJ, Frey MR, Miguel JC, Burkitt MD, et al. A mouse model of pathological small intestinal epithelial cell apoptosis and shedding induced by systemic administration of lipopolysaccharide. Dis Model Mech 2013;6:1388-99.
11. Turner JR. Molecular basis of epithelial barrier regulation - from basic mechanisms to clinical application. Am J Pathol 2006;169:1901-9.
12. Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol 2010;87:79-92.
13. Lai YP, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009;30:131-41.
14. Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, et al. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 1997;272:13088-93.
15. Mookherjee N, Brown KL, Bowdish DME, Doria S, Falsafi R, Hokamp K, et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006;176:2455-64.
16. Nell MJ, Tjabringa GS, Wafelman AR, Verrijk R, Hiemstra PS, Drijfhout JW, et al. Development of novel LL-37 derived antimicrobial peptides with LIPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 2006;27:649-60.
17. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002;169:3883-91.
18. Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K, et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006;18:615-21.
19. Ye Y, Xing H, Chen X. Anti-inflammatory and analgesic activities of the hydrolyzed sasanquasaponins from the defatted seeds of Camellia oleifera . Arch Pharm Res 2013;36:941-51.
20. Tai EKK, Wu WKK, Wong HPS, Lam EKY, Yu L, Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med 2007;232:799-808.
21. Wang YP, Zhang ZY, Chen LL, Guang HJ, Li Z, Yang HL, et al. Cathelicidin-BF, a snake cathelicidin-derived antimicrobial peptide, could be an excellent therapeutic agent for Acne vulgaris. PLoS ONE 2011;6.
22. Wang Y, Hong J, Liu X, Yang H, Liu R, Wu J, et al. Snake cathelicidin from Bungarus fasciatus is a potent peptide antibiotics. PLoS ONE 2008;3:e3217.
23. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671-5.
24. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in lowflow states 1. a morphological, hemodynamic, and metabolic reappraisal. Arch Surg 1970;101:478-&.
25. Gu LL, Li N, Gong JF, Li QR, Zhu WM, Li JS. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis 2011;203:1602-12.
26. Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012;61:1146-53.
27. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation Host R. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005;12:60-7.
28. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010;10:131-43.
29. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YCE, Mathison J, et al. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316:552-4.
30. Chin AC, Flynn AN, Fedwick JP, Buret AG. The role of caspase-3 in lipopolysaccharide-mediated disruption of intestinal epithelial tight junctions. Can J Physiol Pharmacol 2006;84:1043-50.
31. Park EJ, Thomson ABR, Clandinin MT. Protection of intestinal occludin tight junction protein by dietary gangliosides in lipopolysaccharide-induced acute inflammation. J Pediatr Gastroenterol Nutr 2010;50:321-8.
32. Al-Sadi R, Khatib K, Guo SH, Ye DM, Youssef M, Ma T. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2011;300:G1054-64.
33. Ma TY, Boivin MA, Ye DM, Pedram A, Said HM. Mechanism of TNF-alpha modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005;288:G422-30.
34. Al-Sadi R, Ye DM, Dokladny K, Ma TY. Mechanism of IL-1 beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 2008;180:5653-61.
35. Ranaivo HR, Carusio N, Wangensteen R, Ohlmann P, Loichot C, Tesse A, et al. Protection against endotoxic shock as a consequence of reduced nitrosative stress in MLCK210-null mice. Am J Pathol 2007;170:439-46.